Second allogeneic transplants for multiple myeloma: a report from the EBMT Chronic Malignancies Working Party

Patrick J Hayden; Dirk-Jan Eikema; Liesbeth C de Wreede; Linda Koster; Nicolaus Kröger; Hermann Einsele; Monique Minnema; Alida Dominietto; Michael Potter; Jacob Passweg; Arancha Bermúdez; Stephanie Nguyen-Quoc; Uwe Platzbecker; Johanna Tischer; Fabio Ciceri; Joan Hendrik Veelken; Per Ljungman; Nicolaas Schaap; Edouard Forcade; Angelo Michele Carella; Virginie Gandemer; William Arcese; Adrian Bloor; Attilio Olivieri; Laure Vincent; Meral Beksac; Stefan Schönland; Ibrahim Yakoub-Agha

doi:10.1038/s41409-021-01286-x

Second allogeneic transplants for multiple myeloma: a report from the EBMT Chronic Malignancies Working Party

Patrick J Hayden, Dirk-Jan Eikema, Liesbeth C de Wreede, Linda Koster, Nicolaus Kröger, Hermann Einsele, Monique Minnema, Alida Dominietto, Michael Potter, Jacob Passweg, Arancha Bermúdez, Stephanie Nguyen-Quoc, Uwe Platzbecker, Johanna Tischer, Fabio Ciceri, Joan Hendrik Veelken, Per Ljungman, Nicolaas Schaap, Edouard Forcade, Angelo Michele CarellaVirginie Gandemer, William Arcese, Adrian Bloor, Attilio Olivieri, Laure Vincent, Meral Beksac, Stefan Schönland, Ibrahim Yakoub-Agha

Research output: Contribution to journal › Article › Academic › peer-review

12 Downloads (Pure)

Abstract

The EBMT Chronic Malignancies Working Party performed a retrospective analysis of 215 patients who underwent a second allo-HCT for myeloma between 1994 and 2017, 159 for relapse and 56 for graft failure. In the relapse group, overall survival (OS) was 38% (30-46%) at 2 years and 25% (17-32%) at 5 years. Patients who had a HLA-identical sibling (HLAid-Sib) donor for their first and second transplants had superior OS (5 year OS: HLAid-Sib/HLAid-Sib: 35% (24-46%); Others 9% (0-17%), p < 0.001). There was a significantly higher incidence of acute grade II-IV GvHD in those patients who had also developed GvHD following their initial HLA-identical sibling allo-HCT (HLAid-Sib/HLAid-Sib: 50% (33-67%); Other 22% (8-36%), p = 0.03). More as opposed to fewer than 2 years between transplants was associated with superior 5-yr OS (31% (21-40%) vs. 10% (1-20%), P = 0.005). On multivariate analysis, consecutive HLA-identical sibling donor transplants conferred a significant OS advantage (0.4 (0.24-0.67), p < 0.001). In the graft failure group, OS was 41% at 2 years. In summary, a second allo-HCT using a HLA-identical sibling donor, if available, provides the best transplant outcomes for relapsed myeloma in this setting.

Original language	English
Pages (from-to)	2367-2381
Number of pages	15
Journal	Bone Marrow Transplantation
Volume	56
Issue number	10
Early online date	11 May 2021
DOIs	https://doi.org/10.1038/s41409-021-01286-x
Publication status	Published - Oct 2021

Access to Document

10.1038/s41409-021-01286-xLicence: CC BY

s41409-021-01286-xFinal published version, 1.05 MBLicence: CC BY

Cite this

Hayden, P. J., Eikema, D.-J., de Wreede, L. C., Koster, L., Kröger, N., Einsele, H., Minnema, M., Dominietto, A., Potter, M., Passweg, J., Bermúdez, A., Nguyen-Quoc, S., Platzbecker, U., Tischer, J., Ciceri, F., Veelken, J. H., Ljungman, P., Schaap, N., Forcade, E., ... Yakoub-Agha, I. (2021). Second allogeneic transplants for multiple myeloma: a report from the EBMT Chronic Malignancies Working Party. Bone Marrow Transplantation, 56(10), 2367-2381. https://doi.org/10.1038/s41409-021-01286-x

@article{8d59b318f2d647ac83aa00c3032e9eab,

title = "Second allogeneic transplants for multiple myeloma: a report from the EBMT Chronic Malignancies Working Party",

abstract = "The EBMT Chronic Malignancies Working Party performed a retrospective analysis of 215 patients who underwent a second allo-HCT for myeloma between 1994 and 2017, 159 for relapse and 56 for graft failure. In the relapse group, overall survival (OS) was 38% (30-46%) at 2 years and 25% (17-32%) at 5 years. Patients who had a HLA-identical sibling (HLAid-Sib) donor for their first and second transplants had superior OS (5 year OS: HLAid-Sib/HLAid-Sib: 35% (24-46%); Others 9% (0-17%), p < 0.001). There was a significantly higher incidence of acute grade II-IV GvHD in those patients who had also developed GvHD following their initial HLA-identical sibling allo-HCT (HLAid-Sib/HLAid-Sib: 50% (33-67%); Other 22% (8-36%), p = 0.03). More as opposed to fewer than 2 years between transplants was associated with superior 5-yr OS (31% (21-40%) vs. 10% (1-20%), P = 0.005). On multivariate analysis, consecutive HLA-identical sibling donor transplants conferred a significant OS advantage (0.4 (0.24-0.67), p < 0.001). In the graft failure group, OS was 41% at 2 years. In summary, a second allo-HCT using a HLA-identical sibling donor, if available, provides the best transplant outcomes for relapsed myeloma in this setting.",

author = "Hayden, {Patrick J} and Dirk-Jan Eikema and {de Wreede}, {Liesbeth C} and Linda Koster and Nicolaus Kr{\"o}ger and Hermann Einsele and Monique Minnema and Alida Dominietto and Michael Potter and Jacob Passweg and Arancha Berm{\'u}dez and Stephanie Nguyen-Quoc and Uwe Platzbecker and Johanna Tischer and Fabio Ciceri and Veelken, {Joan Hendrik} and Per Ljungman and Nicolaas Schaap and Edouard Forcade and Carella, {Angelo Michele} and Virginie Gandemer and William Arcese and Adrian Bloor and Attilio Olivieri and Laure Vincent and Meral Beksac and Stefan Sch{\"o}nland and Ibrahim Yakoub-Agha",

note = "Publisher Copyright: {\textcopyright} 2021, The Author(s).",

year = "2021",

month = oct,

doi = "10.1038/s41409-021-01286-x",

language = "English",

volume = "56",

pages = "2367--2381",

journal = "Bone Marrow Transplantation",

issn = "0268-3369",

publisher = "Nature Publishing Group",

number = "10",

}

Hayden, PJ, Eikema, D-J, de Wreede, LC, Koster, L, Kröger, N, Einsele, H, Minnema, M, Dominietto, A, Potter, M, Passweg, J, Bermúdez, A, Nguyen-Quoc, S, Platzbecker, U, Tischer, J, Ciceri, F, Veelken, JH, Ljungman, P, Schaap, N, Forcade, E, Carella, AM, Gandemer, V, Arcese, W, Bloor, A, Olivieri, A, Vincent, L, Beksac, M, Schönland, S & Yakoub-Agha, I 2021, 'Second allogeneic transplants for multiple myeloma: a report from the EBMT Chronic Malignancies Working Party', Bone Marrow Transplantation, vol. 56, no. 10, pp. 2367-2381. https://doi.org/10.1038/s41409-021-01286-x

TY - JOUR

T1 - Second allogeneic transplants for multiple myeloma

T2 - a report from the EBMT Chronic Malignancies Working Party

AU - Hayden, Patrick J

AU - Eikema, Dirk-Jan

AU - de Wreede, Liesbeth C

AU - Koster, Linda

AU - Kröger, Nicolaus

AU - Einsele, Hermann

AU - Minnema, Monique

AU - Dominietto, Alida

AU - Potter, Michael

AU - Passweg, Jacob

AU - Bermúdez, Arancha

AU - Nguyen-Quoc, Stephanie

AU - Platzbecker, Uwe

AU - Tischer, Johanna

AU - Ciceri, Fabio

AU - Veelken, Joan Hendrik

AU - Ljungman, Per

AU - Schaap, Nicolaas

AU - Forcade, Edouard

AU - Carella, Angelo Michele

AU - Gandemer, Virginie

AU - Arcese, William

AU - Bloor, Adrian

AU - Olivieri, Attilio

AU - Vincent, Laure

AU - Beksac, Meral

AU - Schönland, Stefan

AU - Yakoub-Agha, Ibrahim

PY - 2021/10

Y1 - 2021/10

N2 - The EBMT Chronic Malignancies Working Party performed a retrospective analysis of 215 patients who underwent a second allo-HCT for myeloma between 1994 and 2017, 159 for relapse and 56 for graft failure. In the relapse group, overall survival (OS) was 38% (30-46%) at 2 years and 25% (17-32%) at 5 years. Patients who had a HLA-identical sibling (HLAid-Sib) donor for their first and second transplants had superior OS (5 year OS: HLAid-Sib/HLAid-Sib: 35% (24-46%); Others 9% (0-17%), p < 0.001). There was a significantly higher incidence of acute grade II-IV GvHD in those patients who had also developed GvHD following their initial HLA-identical sibling allo-HCT (HLAid-Sib/HLAid-Sib: 50% (33-67%); Other 22% (8-36%), p = 0.03). More as opposed to fewer than 2 years between transplants was associated with superior 5-yr OS (31% (21-40%) vs. 10% (1-20%), P = 0.005). On multivariate analysis, consecutive HLA-identical sibling donor transplants conferred a significant OS advantage (0.4 (0.24-0.67), p < 0.001). In the graft failure group, OS was 41% at 2 years. In summary, a second allo-HCT using a HLA-identical sibling donor, if available, provides the best transplant outcomes for relapsed myeloma in this setting.

AB - The EBMT Chronic Malignancies Working Party performed a retrospective analysis of 215 patients who underwent a second allo-HCT for myeloma between 1994 and 2017, 159 for relapse and 56 for graft failure. In the relapse group, overall survival (OS) was 38% (30-46%) at 2 years and 25% (17-32%) at 5 years. Patients who had a HLA-identical sibling (HLAid-Sib) donor for their first and second transplants had superior OS (5 year OS: HLAid-Sib/HLAid-Sib: 35% (24-46%); Others 9% (0-17%), p < 0.001). There was a significantly higher incidence of acute grade II-IV GvHD in those patients who had also developed GvHD following their initial HLA-identical sibling allo-HCT (HLAid-Sib/HLAid-Sib: 50% (33-67%); Other 22% (8-36%), p = 0.03). More as opposed to fewer than 2 years between transplants was associated with superior 5-yr OS (31% (21-40%) vs. 10% (1-20%), P = 0.005). On multivariate analysis, consecutive HLA-identical sibling donor transplants conferred a significant OS advantage (0.4 (0.24-0.67), p < 0.001). In the graft failure group, OS was 41% at 2 years. In summary, a second allo-HCT using a HLA-identical sibling donor, if available, provides the best transplant outcomes for relapsed myeloma in this setting.

UR - http://www.scopus.com/inward/record.url?scp=85105797196&partnerID=8YFLogxK

U2 - 10.1038/s41409-021-01286-x

DO - 10.1038/s41409-021-01286-x

M3 - Article

C2 - 33976382

SN - 0268-3369

VL - 56

SP - 2367

EP - 2381

JO - Bone Marrow Transplantation

JF - Bone Marrow Transplantation

IS - 10

ER -

Second allogeneic transplants for multiple myeloma: a report from the EBMT Chronic Malignancies Working Party

Abstract

Access to Document

Other files and links

Fingerprint

Cite this